MoonLake Immunotherapeutics (MLTX) director receives 22,195 stock options grant

Rhea-AI Filing Summary

MoonLake Immunotherapeutics director Catherine Moukheibir received a grant of options to buy 22,195 Class A ordinary shares. The options have an exercise price of $19.19 per share and expire on June 17, 2036. All 22,195 options are shown as held directly after the transaction.

According to the terms, the options will vest in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders, as long as she continues to serve the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Moukheibir Catherine

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to Buy	22,195	$0.00	--

Holdings After Transaction: Option to Buy — 22,195 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 22,195 options Exercise price: $19.19 per share Underlying shares: 22,195 shares +3 more

6 metrics

Options granted 22,195 options Grant to director on June 17, 2026

Exercise price $19.19 per share Option strike price for Class A ordinary shares

Underlying shares 22,195 shares Class A ordinary shares tied to the options

Expiration date June 17, 2036 Options’ expiration

Post-transaction options held 22,195 options Total derivative holdings after this grant

Vesting deadline June 17, 2027 or next AGM Options vest in full at the earlier date

Key Terms

Option to Buy, Class A ordinary shares, exercise price, expiration date, +1 more

5 terms

Option to Buy financial

"security_title: "Option to Buy""

Class A ordinary shares financial

"underlying_security_title: "Class A ordinary shares, par value $0.0001 per share""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

exercise price financial

"conversion_or_exercise_price: "19.1900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-17T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"which will vest in full the earlier of (i) June 17, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moukheibir Catherine

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Buy	$19.19	06/17/2026		A		22,195		(1)	06/17/2036	Class A ordinary shares, par value $0.0001 per share	22,195	$0.00	22,195	D

Explanation of Responses:

1. This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) report for Catherine Moukheibir?

MoonLake Immunotherapeutics reported that director Catherine Moukheibir received a grant of options to buy 22,195 Class A ordinary shares. These options were awarded as compensation, not purchased on the open market, and are reflected as directly held following the transaction.

What are the key terms of Catherine Moukheibir’s option grant at MoonLake Immunotherapeutics (MLTX)?

The grant covers 22,195 options with an exercise price of $19.19 per share and an expiration date of June 17, 2036. Each option is tied to one Class A ordinary share, providing long-dated equity compensation linked to MoonLake’s share performance.

When do Catherine Moukheibir’s MoonLake (MLTX) options vest?

The options vest in full on the earlier of June 17, 2027 or the date of MoonLake’s next annual general meeting of shareholders. Vesting is conditional on her continued service to the company through that vesting date, aligning incentives with ongoing board participation.

How many MoonLake (MLTX) options does Catherine Moukheibir hold after this Form 4 transaction?

Following this transaction, the filing shows Catherine Moukheibir holding 22,195 options related to MoonLake Class A ordinary shares. This matches the number of options granted in this award, indicating the full grant amount is now reflected in her reported derivative holdings.

Is Catherine Moukheibir’s MoonLake (MLTX) option grant an open-market buy or compensation award?

The transaction is coded as a grant or award acquisition, not an open-market purchase. She received 22,195 options at a $19.19 exercise price as part of her compensation as a director, with vesting tied to continued service and a long-dated expiration in 2036.